Difference between revisions of "Lipid nanoparticle"

From Wikispooks
Jump to navigation Jump to search
(Important subject, but maybe a bit too technical. First approved for use only in 2018.)
 
 
(2 intermediate revisions by 2 users not shown)
Line 6: Line 6:
 
|image_caption=Solid lipid nanoparticles (SLNs). There is only one phospholipid layer because the bulk of the interior of the particle is composed of lipophilic substance. Payloads such as modified RNA, RNA vaccine or others can be embedded in the interior, as desired. Optionally, targeting-molecules such as antibodies, cell-targeting peptides, and/or other drug molecules can be bound to the exterior surface of the SLN.
 
|image_caption=Solid lipid nanoparticles (SLNs). There is only one phospholipid layer because the bulk of the interior of the particle is composed of lipophilic substance. Payloads such as modified RNA, RNA vaccine or others can be embedded in the interior, as desired. Optionally, targeting-molecules such as antibodies, cell-targeting peptides, and/or other drug molecules can be bound to the exterior surface of the SLN.
 
|constitutes=medical technology,nanomaterial
 
|constitutes=medical technology,nanomaterial
−
|description=Discovered in 2018, LNPs used in [[modified-RNA vaccines]] for [[SARS-CoV-2]].
+
|description=First used in 2018, LNPs are now used in [[modified-RNA vaccines]] for [[SARS-CoV-2]].
 
}}
 
}}
−
'''Lipid nanoparticles''' (LNPs) are a recently discovered (2018) [[drug delivery systems|pharmaceutical drug delivery system]].
+
'''Lipid nanoparticles''' (LNPs) is a [[pharmaceutical drug delivery system]] discovered as recently as [[2018]].
  
−
As of late 2020, several mRNA vaccines for SARS-CoV-2 use LNPs as their drug delivery system, including both the [[Moderna COVID-19]] vaccine and the [[Pfizer–BioNTech COVID-19 vaccines]].<ref name=Stat4>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906799</ref> [[Moderna]] uses its own proprietary ionizable cationic lipid called [[SM-102]], while [[Pfizer]] and [[BioNTech]] licensed an ionizable cationic lipid called [[ALC-0315]] from the company [[Acuitas]].<ref name="Cross">https://cen.acs.org/pharmaceuticals/drug-delivery/Without-lipid-shells-mRNA-vaccines/99/i8</ref>
+
From late 2020, several mRNA vaccines for SARS-CoV-2 use LNPs as their drug delivery system, including both the [[Moderna COVID-19]] vaccine and the [[Pfizer–BioNTech COVID-19 vaccines]].<ref name=Stat4>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906799</ref> [[Moderna]] uses its own proprietary ionizable cationic lipid called [[SM-102]], while [[Pfizer]] and [[BioNTech]] licensed an ionizable cationic lipid called [[ALC-0315]] from the company [[Acuitas]].<ref name="Cross">https://cen.acs.org/pharmaceuticals/drug-delivery/Without-lipid-shells-mRNA-vaccines/99/i8</ref>
  
 
==Lipid==
 
==Lipid==
 
A lipid is a type of organic molecule found in living things. It is oily or waxy. Fats are made from lipid molecules. Lipids are a group of naturally occurring molecules that include fats, waxes, sterols, fat-soluble vitamins (such as vitamins A, D, E, and K), glycerides, phospholipids, and others. Lipids are classified as simple and complex. Examples of complex molecules could be [[steroids]] or phospholipids.  A very important biological function of lipids is as lipid bilayers, the basis of many cell membranes. Another function of lipids is to serve as an energy reserve.  The main biological functions of lipids include storing energy, signalling, and acting as components of cell membranes.<ref>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2674711</ref>
 
A lipid is a type of organic molecule found in living things. It is oily or waxy. Fats are made from lipid molecules. Lipids are a group of naturally occurring molecules that include fats, waxes, sterols, fat-soluble vitamins (such as vitamins A, D, E, and K), glycerides, phospholipids, and others. Lipids are classified as simple and complex. Examples of complex molecules could be [[steroids]] or phospholipids.  A very important biological function of lipids is as lipid bilayers, the basis of many cell membranes. Another function of lipids is to serve as an energy reserve.  The main biological functions of lipids include storing energy, signalling, and acting as components of cell membranes.<ref>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2674711</ref>
−
 
−
== Applications ==
 
−
Development of solid lipid [[nanoparticle]]s is one of the emerging fields of lipid nanotechnology  with several potential applications in drug delivery, [[clinical medicine]] and [[research]], as well as in other disciplines.  Due to their unique size-dependent properties, lipid nanoparticles offer the possibility to develop new therapeutics.  The ability to incorporate drugs into nanocarriers offers a new prototype in drug delivery that could hold great promise for attaining the bioavailability enhancement along with controlled and site-specific drug delivery. SLN's are also considered to well tolerated in general, due to their composition from physiologically similar lipids.
 
  
 
==History==
 
==History==
Line 23: Line 20:
 
During the late 1990s and 2000s, [[Pieter Cullis]] of the [[University of British Columbia]] developed ionizable cationic lipids which are "positively charged at an acidic pH but neutral in the blood."<ref name="Cross" /> Cullis also led the development of a technique involving careful adjustments to pH during the process of mixing ingredients in order to create LNPs which could safely pass through the cell membranes of living organisms.<ref name="Foley" >https://qz.com/1948132/the-first-covid-19-vaccines-have-changed-biotech-forever/</ref><ref name="Cullis_2017">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498813</ref>   
 
During the late 1990s and 2000s, [[Pieter Cullis]] of the [[University of British Columbia]] developed ionizable cationic lipids which are "positively charged at an acidic pH but neutral in the blood."<ref name="Cross" /> Cullis also led the development of a technique involving careful adjustments to pH during the process of mixing ingredients in order to create LNPs which could safely pass through the cell membranes of living organisms.<ref name="Foley" >https://qz.com/1948132/the-first-covid-19-vaccines-have-changed-biotech-forever/</ref><ref name="Cullis_2017">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498813</ref>   
  
−
As of [[2021]], the current understanding of LNPs formulated with such ionizable cationic lipids is that they enter cells through [[receptor-mediated endocytosis]] and end up inside [[endosome]]s.<ref name="Cross" /> The acidity inside the endosomes causes LNPs' ionizable cationic lipids to acquire a positive charge, and this is thought to allow LNPs to escape from endosomes and release their RNA payloads.<ref name="Cross" />
+
From 2005 into the early 2010s, LNPs were investigated as a drug delivery system for [[small interfering RNA]] (siRNA) drugs.<ref name="Cross" />  In 2009, Cullis co-founded a company called Acuitas Therapeutics to commercialize his LNP research; Acuitas worked on developing LNPs for [[Alnylam Pharmaceuticals]]'s siRNA drugs.<ref name="Shore">https://vancouversun.com/news/local-news/covid-19-vancouvers-acuitas-therapeutics-a-key-contributor-to-coronavirus-solution</ref> In 2018, the FDA approved Alnylam's siRNA drug Onpattro ([[patisiran]]), the first drug to use LNPs as the drug delivery system.<ref name=Stat4/><ref name="Cross" />  
 +
 
 +
==Moderna and BioNTech==
 +
From late 2020, several mRNA vaccines for SARS-CoV-2 use LNPs as their drug delivery system, including both the Moderna COVID-19 vaccine and the Pfizer–BioNTech COVID-19 vaccines.<ref name=Stat4/> [[Moderna]] uses its own proprietary ionizable cationic lipid called [[SM-102]], while [[Pfizer]] and [[BioNTech]] licensed an ionizable cationic lipid called [[ALC-0315]] from Acuitas.<ref name="Cross" />
  
−
From 2005 into the early 2010s, LNPs were investigated as a drug delivery system for [[small interfering RNA]] (siRNA) drugs.<ref name="Cross" /> In 2009, Cullis co-founded a company called Acuitas Therapeutics to commercialize his LNP research; Acuitas worked on developing LNPs for [[Alnylam Pharmaceuticals]]'s siRNA drugs.<ref name="Shore">https://vancouversun.com/news/local-news/covid-19-vancouvers-acuitas-therapeutics-a-key-contributor-to-coronavirus-solution</ref> In 2018, the FDA approved Alnylam's siRNA drug Onpattro ([[patisiran]]), the first drug to use LNPs as the drug delivery system.<ref name=Stat4/><ref name="Cross" />  
+
The synthetic ionizable lipid in the Pfizer SARS-CoV-2 vaccine is believed to have a half-life of around 20-30 days in humans.<ref>https://tkp.at/2021/12/09/wesentliche-daten-fehlen-bei-bedingter-biontech-pfizer-zulassung-in-eu-alc/</ref>
 +
 
 +
===Philadelphia study===
 +
A December [[2021]] study from [[Thomas Jefferson University]], [[Philadelphia]] showed that injection of the LNPs used by [[BioNTech]] and [[Modern]] leads to rapid and powerful inflammatory responses. This could explain their potent [[adjuvant]] effect. Intranasal administration with higher doses of LNPs resulted in a significant mortality rate.<ref name=sciencedirect>https://www.sciencedirect.com/science/article/pii/S2589004221014504</ref><ref>https://tkp.at/2021/12/22/so-verursachen-lipid-nanopartikel-in-gentechnik-impfstoffen-durch-entzuendungen-schwere-nebenwirkungen/</ref>
 +
 
 +
The mechanism of action of the mRNA component is modified in such a way that it reduces the activation of sensors of the innate [[immune system]]. People who received the vaccine often had typical acute side effects of inflammation, such as pain, swelling, and fever. The inflammatory responses triggered solely by the LNPs or together with mRNAs were independent of the route of administration. They are therefore responsible for a range of extremely serious side effects.<ref name=sciencedirect/>
  
−
Lipids intended for short siRNA strands did not work well for much longer mRNA strands, which led to extensive research during the mid-2010s into the creation of novel ionizable cationic lipids appropriate for mRNA.<ref name="Cross" />
+
===Threats against researcher===
 +
German Cell biologist [[Vanessa Schmidt-Krüger ]]explained in detail what the Philadelphia researchers concluded in two videos already at end of [[2020]]<ref>https://tkp.at/2021/01/03/gefahren-ausgehend-von-lipidnanopartikeln-in-mrna-impfstoffen/</ref>. After the explanations presented a very uncomfortable truth for the vaccine producers, the scientist and her family were severely threatened. She then withdrew almost all of the videos, explaining:
  
−
As of late 2020, several mRNA vaccines for SARS-CoV-2 use LNPs as their drug delivery system, including both the Moderna COVID-19 vaccine and the Pfizer–BioNTech COVID-19 vaccines.<ref name=Stat4/> [[Moderna]] uses its own proprietary ionizable cationic lipid called [[SM-102]], while [[Pfizer]] and [[BioNTech]] licensed an ionizable cationic lipid called [[ALC-0315]] from Acuitas.<ref name="Cross" />
+
{{QB|In order to avert harm to myself and the people who are important to me, I feel compelled to delete informational videos. My intention was to publish my private opinion on the basis of scientific facts and to convey my knowledge and experience as a cell biologist to a broad audience in an understandable way. I would have gladly continued my work and published my other videos. I would be happy if it becomes possible again in the future.<ref>https://tkp.at/2021/01/03/gefahren-ausgehend-von-lipidnanopartikeln-in-mrna-impfstoffen/</ref>}}
  
−
==Production==
+
===Patent litigation===
−
Different formulation procedures include high shear homogenization and ultrasound, solvent emulsification/evaporation, or microemulsion. Obtaining size distributions in the range of 30-180 nm is possible using ultrasonification at the cost of long sonication time. Ultrasonically produced solid lipid particles exhibit high loading capacities and long-term stability. <ref>Pharmaceuticals Encapsulated in Lipid Nanoparticles with Ultrasonics, https://www.hielscher.com/pharmaceuticals-encapsulated-in-lipid-nanoparticles-with-ultrasonics.htm</ref> Solvent-emulsification, where sonication is often used in order to create nano-emulsions, is suitable in preparing small, homogeneously-sized lipid nanoparticles dispersions with the advantage of avoiding heat.<ref>Wolfgang Mehnert, Karsten Mäder, Solid lipid nanoparticles: Production, characterization and applications, Advanced Drug Delivery Reviews,
 
−
Volume 64, 2012, Pages 83-101, ISSN 0169-409X, https://doi.org/10.1016/j.addr.2012.09.021</ref>
 
  
 +
On March 10, 2023, U.S. District Judge [[Mitchell Goldberg]] rejected a bid by [[Moderna]] to dismiss some of the patent infringement claims brought against the company by [[Arbutus Biopharma]] and its partner, [[Genevant Sciences]].<ref>Stieber, Z. (2023, March 13). ''Judge Rejects Request From Moderna, Moving Key COVID-19 Vaccine Case to Discovery.'' The Epoch Times. http://archive.today/2023.03.13-173504/https://www.theepochtimes.com/judge-rejects-request-from-moderna-moving-key-covid-19-vaccine-case-to-discovery_5119082.html</ref><ref>Goldberg, M. (2023). ''Case 1:22-cv-00252-MSG Document 64.'' Document Cloud; United States District Court for the District of Delaware. https://web.archive.org/web/20230316161451/https://s3.documentcloud.org/documents/23706145/moderna-covid-19-opinion.pdf</ref>
  
 
{{SMWDocs}}
 
{{SMWDocs}}
 +
 
==References==
 
==References==
 
{{reflist}}
 
{{reflist}}

Latest revision as of 16:01, 25 August 2023

Concept.png Lipid nanoparticle 
(medical technology,  nanomaterial)Rdf-entity.pngRdf-icon.png
Lipid nanoparticle.png
Solid lipid nanoparticles (SLNs). There is only one phospholipid layer because the bulk of the interior of the particle is composed of lipophilic substance. Payloads such as modified RNA, RNA vaccine or others can be embedded in the interior, as desired. Optionally, targeting-molecules such as antibodies, cell-targeting peptides, and/or other drug molecules can be bound to the exterior surface of the SLN.
Start2018
First used in 2018, LNPs are now used in modified-RNA vaccines for SARS-CoV-2.

Lipid nanoparticles (LNPs) is a pharmaceutical drug delivery system discovered as recently as 2018.

From late 2020, several mRNA vaccines for SARS-CoV-2 use LNPs as their drug delivery system, including both the Moderna COVID-19 vaccine and the Pfizer–BioNTech COVID-19 vaccines.[1] Moderna uses its own proprietary ionizable cationic lipid called SM-102, while Pfizer and BioNTech licensed an ionizable cationic lipid called ALC-0315 from the company Acuitas.[2]

Lipid

A lipid is a type of organic molecule found in living things. It is oily or waxy. Fats are made from lipid molecules. Lipids are a group of naturally occurring molecules that include fats, waxes, sterols, fat-soluble vitamins (such as vitamins A, D, E, and K), glycerides, phospholipids, and others. Lipids are classified as simple and complex. Examples of complex molecules could be steroids or phospholipids. A very important biological function of lipids is as lipid bilayers, the basis of many cell membranes. Another function of lipids is to serve as an energy reserve. The main biological functions of lipids include storing energy, signalling, and acting as components of cell membranes.[3]

History

A significant obstacle to using LNPs as a delivery vehicle for nucleic acids is that in nature, lipids and nucleic acids both carry a negative electric charge—meaning they do not easily mix with each other.[4] While working at Syntex in the mid-1980s,[5] Philip Felgner pioneered the use of artificially-created cationic lipids (positively-charged lipids) to bind lipids to nucleic acids in order to transfect the latter into cells.[6] However, by the late 1990s, it was known from in vitro experiments that this use of cationic lipids had undesired side effects on cell membranes.[7]

During the late 1990s and 2000s, Pieter Cullis of the University of British Columbia developed ionizable cationic lipids which are "positively charged at an acidic pH but neutral in the blood."[2] Cullis also led the development of a technique involving careful adjustments to pH during the process of mixing ingredients in order to create LNPs which could safely pass through the cell membranes of living organisms.[4][8]

From 2005 into the early 2010s, LNPs were investigated as a drug delivery system for small interfering RNA (siRNA) drugs.[2] In 2009, Cullis co-founded a company called Acuitas Therapeutics to commercialize his LNP research; Acuitas worked on developing LNPs for Alnylam Pharmaceuticals's siRNA drugs.[9] In 2018, the FDA approved Alnylam's siRNA drug Onpattro (patisiran), the first drug to use LNPs as the drug delivery system.[1][2]

Moderna and BioNTech

From late 2020, several mRNA vaccines for SARS-CoV-2 use LNPs as their drug delivery system, including both the Moderna COVID-19 vaccine and the Pfizer–BioNTech COVID-19 vaccines.[1] Moderna uses its own proprietary ionizable cationic lipid called SM-102, while Pfizer and BioNTech licensed an ionizable cationic lipid called ALC-0315 from Acuitas.[2]

The synthetic ionizable lipid in the Pfizer SARS-CoV-2 vaccine is believed to have a half-life of around 20-30 days in humans.[10]

Philadelphia study

A December 2021 study from Thomas Jefferson University, Philadelphia showed that injection of the LNPs used by BioNTech and Modern leads to rapid and powerful inflammatory responses. This could explain their potent adjuvant effect. Intranasal administration with higher doses of LNPs resulted in a significant mortality rate.[11][12]

The mechanism of action of the mRNA component is modified in such a way that it reduces the activation of sensors of the innate immune system. People who received the vaccine often had typical acute side effects of inflammation, such as pain, swelling, and fever. The inflammatory responses triggered solely by the LNPs or together with mRNAs were independent of the route of administration. They are therefore responsible for a range of extremely serious side effects.[11]

Threats against researcher

German Cell biologist Vanessa Schmidt-Krüger explained in detail what the Philadelphia researchers concluded in two videos already at end of 2020[13]. After the explanations presented a very uncomfortable truth for the vaccine producers, the scientist and her family were severely threatened. She then withdrew almost all of the videos, explaining:


In order to avert harm to myself and the people who are important to me, I feel compelled to delete informational videos. My intention was to publish my private opinion on the basis of scientific facts and to convey my knowledge and experience as a cell biologist to a broad audience in an understandable way. I would have gladly continued my work and published my other videos. I would be happy if it becomes possible again in the future.[14]

Patent litigation

On March 10, 2023, U.S. District Judge Mitchell Goldberg rejected a bid by Moderna to dismiss some of the patent infringement claims brought against the company by Arbutus Biopharma and its partner, Genevant Sciences.[15][16]


Many thanks to our Patrons who cover ~2/3 of our hosting bill. Please join them if you can.



References

  1. ↑ a b c https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906799
  2. ↑ a b c d e https://cen.acs.org/pharmaceuticals/drug-delivery/Without-lipid-shells-mRNA-vaccines/99/i8
  3. ↑ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2674711
  4. ↑ a b https://qz.com/1948132/the-first-covid-19-vaccines-have-changed-biotech-forever/
  5. ↑ {https://library.ucsd.edu/sdta/transcripts/felgner-phil_19970722.html
  6. ↑ https://www.google.com/books/edition/Pharmaceutical_Perspectives_of_Nucleic_A/XKgb-xbnTlUC?hl=en&gbpv=1&pg=PA275&printsec=frontcover
  7. ↑ https://www.google.com/books/edition/Liposomes_in_Gene_Delivery/e2bMWl2NZ_4C?hl=en&gbpv=1&pg=PA191&printsec=frontcover
  8. ↑ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498813
  9. ↑ https://vancouversun.com/news/local-news/covid-19-vancouvers-acuitas-therapeutics-a-key-contributor-to-coronavirus-solution
  10. ↑ https://tkp.at/2021/12/09/wesentliche-daten-fehlen-bei-bedingter-biontech-pfizer-zulassung-in-eu-alc/
  11. ↑ a b https://www.sciencedirect.com/science/article/pii/S2589004221014504
  12. ↑ https://tkp.at/2021/12/22/so-verursachen-lipid-nanopartikel-in-gentechnik-impfstoffen-durch-entzuendungen-schwere-nebenwirkungen/
  13. ↑ https://tkp.at/2021/01/03/gefahren-ausgehend-von-lipidnanopartikeln-in-mrna-impfstoffen/
  14. ↑ https://tkp.at/2021/01/03/gefahren-ausgehend-von-lipidnanopartikeln-in-mrna-impfstoffen/
  15. ↑ Stieber, Z. (2023, March 13). Judge Rejects Request From Moderna, Moving Key COVID-19 Vaccine Case to Discovery. The Epoch Times. http://archive.today/2023.03.13-173504/https://www.theepochtimes.com/judge-rejects-request-from-moderna-moving-key-covid-19-vaccine-case-to-discovery_5119082.html
  16. ↑ Goldberg, M. (2023). Case 1:22-cv-00252-MSG Document 64. Document Cloud; United States District Court for the District of Delaware. https://web.archive.org/web/20230316161451/https://s3.documentcloud.org/documents/23706145/moderna-covid-19-opinion.pdf


Wikipedia.png This page imported content from Wikipedia on 17.07.2021.
Wikipedia is not affiliated with Wikispooks.   Original page source here
Retrieved from "https://wikispooks.com/w/index.php?title=Lipid_nanoparticle&oldid=267791"